Wistar Scientists Engineer New NK Cell Engaging Immunotherapy Approaches to Target and Potentially Treat Recalcitrant Ovarian Cancer

Novel human Siglec-7 monoclonal and bispecific antibodies are being developed as potential future cancer immunotherapies PHILADELPHIA, PA, Nov. 01 (Korea Bizwire) — The Wistar Institute’s David B. Weiner, Ph.D., executive vice president, director of the Vaccine & Immunotherapy Center (VIC) and W.W. Smith Charitable Trust Distinguished Professor in Cancer Research, and collaborators, have engineered novel monoclonal antibodies that engage [...]